SGEN - Seattle Genetics, Inc.
| Previous Close | 50.79 |
| Open | 50.72 |
| Bid | 40.00 x 100 |
| Ask | 0.00 x 0 |
| Day's Range | 49.48 - 50.95 |
| 52 Week Range | 45.31 - 71.32 |
| Volume | 673,876 |
| Avg. Volume | 1,117,654 |
| Market Cap | 7.84B |
| Beta | 1.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.88 |
| Earnings Date | Apr 26, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.08 |
- American City Business Journals•12 hours ago
Seattle Genetics searches for its 10th building to keep up with growth
The Seattle-area’s largest biotech already has a footprint of about 500,000 square feet, which includes seven office buildings in Bothell, a manufacturing facility in North Creek and a Seattle office.
- Business Wire•8 days ago
Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
Seattle Genetics, Inc. today announced data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate platform technologies as well as its emerging immuno-oncology pipeline.
Markit•15 days agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Business Wire•15 days ago
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018
Seattle Genetics, Inc. announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
- Zacks•22 days ago
Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion
The biotech sector was in focus last week with Protagonist's stock plunging on news of discontinuation of a phase IIb study and Verona Pharma stock surging on positive top-line data from COPD study among others.
- Market Realist•24 days ago
Key Updates on Akcea Therapeutics’ Volanesorsen
How Ionis Pharmaceuticals Is Positioned in 2018
- American City Business Journals•24 days ago
Seattle Genetics wins FDA approval for cancer drug that could push U.S. sales past $1 billion
“This marks the first time in four decades and 10 different attempts to replace one of the most toxic drugs ... for late-stage classical Hodgkin while increasing long-term survival,” founder and CEO Clay Siegall said.
- Market Realist•25 days ago
A Look at Ionis’s Key Revenue Drivers in 4Q17
How Ionis Pharmaceuticals Is Positioned in 2018
- PR Newswire•25 days ago
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., March 26, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics, Inc. (SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI). Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition.
- Business Wire•25 days ago
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics, Inc. and Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate , for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors .
- Zacks•28 days ago
Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
- Zacks•last month
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion
Seattle Genetics' (SGEN) cancer drug, Adcetris, gets FDA approval to include fifth indication, frontline treatment of advanced classical Hodgkin lymphoma, in its label.
- Reuters•last month
Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval
U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, making it the first new treatment in over 40 years. The widely expected approval opens up a key market for Seattle Genetics, which expects the drug to bring in $1 billion in sales within the next few years. "We're 100 percent launch-ready," Chief Executive Clay Siegall said in an interview ahead of the decision.
- Business Wire•last month
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has approved ADCETRIS in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
- American City Business Journals•last month
Seattle Genetics adds second woman to its board with the appointment of Alpna Seth
Seattle Genetics Inc. has appointed Alpna Seth to its board of directors, expanding the board to nine people including two women. Seth’s more than 20 years of experience in health care and biotechnology will help Seattle Genetics continue to build out its growing pipeline of cancer drugs, which includes four applications of its flagship drug Adcetris. “Seattle Genetics is on the cusp of a significant inflection point in its transition into a global, multi-product oncology company,” Seth said in a news release.
- American City Business Journals•last month
Seattle Genetics adds second woman to its board with the appointment of Alpna Seth
Alpna Seth's appointment expands the Seattle biotech's board to nine people including two women. Seth is chief operating officer at San Francisco-based Vir Biotechnology and previously was a senior vice president at Cambridge, Mass.-based Biogen.
- Business Wire•last month
Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors
Seattle Genetics, Inc. announced today that Alpna Seth, Ph.D. has been appointed to the company’s Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry, including senior leadership positions at Biogen.
- Business Wire•last month
Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018
Seattle Genetics, Inc. announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time.
- Motley Fool•last month
Is Celldex Therapeutics Stock About to Skyrocket?
Upcoming results from a clinical study could send this biotech stock into the stratosphere.
- Business Wire•last month
Seattle Genetics Completes Acquisition of Cascadian Therapeutics
Seattle Genetics, Inc. today announced it has completed its previously announced acquisition of Cascadian Therapeutics, Inc. The most advanced program in Cascadian Therapeutics’ pipeline is tucatinib, an investigational oral tyrosine kinase inhibitor that is highly selective for HER2, a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric....
- Business Wire•last month
Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics
Seattle Genetics, Inc. today announced the expiration of the tender offer by a wholly owned subsidiary, “Merger Sub”, for all of the shares of common stock of Cascadian Therapeutics, Inc.
- Zacks•last month
Seattle Genetics (SGEN) Up 8.4% Since Earnings Report: Can It Continue?
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•last month
Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
Seattle Genetics, Inc. today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple myeloma .
- GlobeNewswire•last month
Report: Developing Opportunities within Seattle Genetics, PBF Energy, Chipotle Mexican Grill, CIT Group Inc (DEL), PDL BioPharma, and Dollar General — Future Expectations, Projections Moving into 2018
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
